BNET Industries
Viral Genetics Inc. (VRAL) is in the Pharma Industry
- Profit
- Dec 31 2006
- ($12.6M)
- Market Cap
- Oct 14 2008
- $1.5M
Latest News and Analysis
US approves test for human and bird flu
WASHINGTON AFP — The US Food and Drug Administration has approved a new test that can rapidly diagnose and identify human influenza infections and human bird flu, the agency announced. The test, developed by the US Centers for Disease Control and Prevention, will be available to CDC-qualified laboratories...
Viral Genetics, Inc. Unveils Potential Mechanism of Action in HIV/AIDS Research, Accepted to Present Findings at Prestigious IHV Meeting
Team Welcomes Attendees to Poster Session to Discuss Findings, Which Could Lead to Inexpensive, Effective HIV Therapy, and May Be Applicable to Autoimmune Diseases AZUSA, Calif. -- Viral Genetics, Inc. (Other OTC:VRAL), a biotechnology company that discovers and develops immune-based therapies, today unveiled a new theory regarding a...
Dutton Associates Announces Investment Opinion: Viral Genetics Rating Neutral In Update By Dutton Associates
ROSEVILLE, Calif. -- Dutton Associates updates its coverage of Viral Genetics (OTCBB:VRAL) maintaining a Neutral rating. The 12-page report by Dutton senior analyst Wayne Lottinville, CFA is available at http://www.jmdutton.com/research/VRAL/index.html as well as from First Call, Bloomberg Professional, Zacks, Reuters, Knobias, and other leading financial portals. ...
Viral Genetics Announces Expanded License with University of Colorado and V-Clip Pharmaceuticals
Progress to Date on Licensed HIV/AIDS Technology Leads to New Rights AZUSA, Calif. -- Viral Genetics (Pink Sheets: VRAL) subsidiary V-Clip Pharmaceuticals has expanded the existing Exclusive License Agreement with the University of Colorado by obtaining two Exclusive Option Agreements to acquire rights for treatment...
Genetic vectors research focus
Genetic vectors research focus. Ed. by Pablo S. Ruiz. Nova Biomedical Books 2007 291 pages $129.00 Hardcover QH442 This collection of six brief commentaries and eight articles describes work in plasmids,...
Marshall C. Phelps, Richard T. Gerstner and Anthony Freda, Jr. Join Viral Genetics, Inc. Business Advisory Board and Invest in Private Placement
Viral Genetics, Inc. (PINKSHEETS: VRAL), abiotechnology company, announces that three veteran business executives andhigh-tech investors have joined as the founding members of the Company'sbusiness advisory board. This advisory group has been established as avehicle for experienced business executives to assist and advise theCompany in the development and commercialization of its...
Dutton Associates Announces Investment Opinion: Viral Genetics Rating At Neutral In Update Coverage By Dutton Associates
ROSEVILLE, Calif. -- Dutton Associates updates its coverage of Viral Genetics (Pink Sheets: VRAL) with a Neutral rating. The 10-page report by Dutton senior analyst Wayne Lottinville, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. Viral...
Sequenom Announces Multiple MassARRAY Systems Sales in China
SAN DIEGO -- Sequenom, Inc. (NASDAQ:SQNM), a leading provider of fine mapping genotyping, methylation and gene expression analysis solutions, today announced the sales of multiple MassARRAY([R]) systems in China. Sequenom's new MassARRAY customers include the Beijing Genomics Institute BGI, Asia's largest genetic sequencing center, which plans to initially use the...
Viral Genetics Updates Progress on Technology Acquired From University of Colorado
Viral Genetics, Inc. (PINKSHEETS: VRAL), abiotechnology company, is pleased to announce that it has made additionalprogress in its research as a result of the recent acquisition oftechnology developed by Dr. Karen Newell at the University of Colorado,Colorado Springs (for complete details of the licensing transaction see theCompany's press release and...
ID 12 viruses from single sample
A test that simultaneously detects and identifies 12 specific respiratory viruses has been cleared for marketing. The xTAG Respiratory Viral Panel can differentiate influenza A subtypes H1 and H3; influenza B; respiratory syncytial virus subtypes A and B; parainfluenzas 1,2, and 3; rhinovirus; and adenovirus. Manufactured by Toronto-based Luminex Molecular...
FDA clears first test designed to detect/identify 12 respiratory viruses from single sample
The U.S. Food and Drug Administration has cleared a test that simultaneously detects and identifies 12 specific respiratory viruses. The xTAG Respiratory Viral Panel, is the first test for the detection and differentiation of influenza A subtypes H1 and H3. The new panel is also the first test for human...
AIDS TREATMENT WITH POTENTIAL
A small California company has agreed to license medical technology developed by a local biology professor to research a promising treatment for HIV and AIDS. Under the complex agreement announced last month, Karen Newell, a University of Colorado at Colorado Springs associate biology professor, will spend...
FDA Clears First Test Designed to Detect and Identify 12 Respiratory Viruses from Single Sample.
M2 PRESSWIRE-4 January 2008-US Food and Drug Administration: FDA Clears First Test Designed to Detect and Identify 12 Respiratory Viruses from Single SampleC1994-2008 M2 COMMUNICATIONS LTD RDATE:03012008 The U.S. Food and Drug Administration today cleared for marketing a test...
Viral Genetics Announces Licensing Deal With University of Colorado and V-Clip Pharmaceuticals, Inc.
Viral Genetics, Inc. (PINKSHEETS: VRAL), abiotechnology company that discovers and develops immune-based therapiesfor HIV and AIDS using its thymus nuclear protein ("TNP") compound, hasentered into several agreements with the University of Colorado and V-ClipPharmaceuticals, Inc. relating to the exclusive worldwide rights to patentapplications and know-how developed by Dr. Karen Newell,...
Viral Genetics Appoints Scientific Development Manager to Focus on Translational Studies
Viral Genetics, Inc. (OTCBB: VRAL) has retainedthe services of Michael Agadjanyan, PhD, of the Institute for MolecularMedicine as Acting Director of Preclinical Development. Dr. Agadjanyan hasbeen retained primarily to assist with the implementation of"translational" studies mandated by the development plan for VGV-1, theCompany's HIV/AIDS drug candidate, as outlined by the...
Meningitis test detects viral infection
The FDA cleared a test in March that quickly detects the presence of viral meningitis. In conjunction with other laboratory tests, the Xpert EV test is the first fully automated medical diagnostic test that isolates and amplifies viral genetic material present in a patient's cerebrospinal fluid to aid...
Viral Genetics Builds African Advisory Team
Viral Genetics, Inc. (OTCBB: VRAL) has retainedtwo senior advisors as part of its African advisory team as the Companycontinues the development of VGV-1, the Company's HIV/AIDS product, inAfrica. The two advisors joining the advisory team are Dr. Sam Gulube andMr. Bada Pharasi. Sam Gulube, MD, is the Chairman of the...
Progress on Candidate VGV-1 Sparks Review: Sector Insight.
M2 PRESSWIRE-5 April 2007-Pinnacle Digest: Progress on Candidate VGV-1 Sparks Review: Sector InsightC1994-2007 M2 COMMUNICATIONS LTD RDATE:05042007 To read this article in its entirety, visit www.pinnacledigest.com. Viral Genetics (OTCBB: VRAL) experienced a surge in share value Wednesday combined with...
While Viral Genetics, Inc. Make New Discoveries, Others Update Membership, File New Patent, Announce Availability, Production, and Close Private Placement.
M2 PRESSWIRE-23 March 2007-Stockguru.com: While Viral Genetics, Inc. Make New Discoveries, Others Update Membership, File New Patent, Announce Availability, Production, and Close Private PlacementC1994-2007 M2 COMMUNICATIONS LTD RDATE:23032007 Dallas, Texas - StockGuru Pre-Market Updates for Friday include Neptune Industries, Inc....
Viral Genetics Updates Scientific Milestones
In January of this year Viral Genetics (OTCBB: VRAL) announced that it had preliminarily identified two peptides as theactive components of its HIV/AIDS drug candidate, VGV-1, and further statedits follow up plan to confirm the findings. This research is importantbecause identification of the active components should allow the Company topursue...
- Next »
- page 1 of 1
- « Previous
- Incorporated: 1995
- Employees: 7
Key Competitors
Viral Genetics Inc. Company Info
Board of Directors
Mr. Haig Keledjian
Chairman
Dr. Elizabeth Hoffman Ph.D.
Mr. Arthur Keledjian
Mr. Hampar Karageozian
Mr. Timothy W. Wright III
Mr. Harry Zhabilov Jr.
Dr. Arthur J. Ammann M.D.
Contact Information
1321 Mountain View Circle
Azusa, CA
626 334-5310
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
